SCHEMBL5714968

SCHEMBL5714968

Cc1ccc(CCN2CCN(C(=O)Oc3ccc(CCc4ncccc4C)cc3)CC2)nc1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.42
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.41
AOC3 Q16853 1/20 0.40
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
SIGMAR1 Q99720 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
HTR2A P28223 1/20 0.38
HTR7 P34969 1/20 0.38
OPRM1 P35372 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714564 0.95 SIGMAR1 (0.43) THRBAOC3KDM4EALDH1A1SIGMAR1
SCHEMBL5714829 0.94 TP53 (0.42) TP53LMNATHRBPOLBKDM4E
SCHEMBL6101597 0.90 TP53 (0.52) TP53LMNATHRBKDM4EALDH1A1
SCHEMBL5713945 0.90 SIGMAR1 (0.41) TP53LMNAKDM4EALDH1A1SIGMAR1
SCHEMBL5715262 0.89 AOC3 (0.48) TP53THRBAOC3POLBHRH3
SCHEMBL5714431 0.88 TP53 (0.52) TP53LMNATHRBAOC3KDM4E
SCHEMBL5714902 0.86 THRB (0.41) TP53LMNATHRBPOLBSIGMAR1
SCHEMBL6102660 0.86 TP53 (0.42) TP53LMNATHRBPOLBSIGMAR1
SCHEMBL5716030 0.86 THRB (0.41) TP53LMNATHRBPOLBSIGMAR1
SCHEMBL5714278 0.85 SIGMAR1 (0.43) TP53KDM4EALDH1A1HRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL TP53 2326/4885LMNA 1939/4885THRB 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.